fig6

Figure 6. Schematic representation of EV mediated therapy against NEPC. EVs can be designed to target CEACAM5/other surface antigens and loaded with a variety of therapeutic cargo. Created in BioRender. Saini, S. (2026) https://BioRender.com/orbnahz. EVs: Extracellular vesicles; NEPC: neuroendocrine prostate cancer; siRNA: small interfering RNA; CRISPR/Cas9: clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9; CEACAM5: carcinoembryonic antigen-related cell adhesion molecule 5; EZH2: enhancer of zeste homolog 2; AR: androgen receptor; ASCL1: achaete-scute family bHLH transcription factor 1; BRN2: brain-specific homeobox/POU domain protein 2; FITC: fluorescein isothiocyanate.